Involved free light chain: an early independent predictor of response and progression in multiple myeloma.

Multiple myeloma m-protein progression response serum-free light chain

Journal

Leukemia & lymphoma
ISSN: 1029-2403
Titre abrégé: Leuk Lymphoma
Pays: United States
ID NLM: 9007422

Informations de publication

Date de publication:
09 2021
Historique:
pubmed: 3 4 2021
medline: 25 2 2023
entrez: 2 4 2021
Statut: ppublish

Résumé

Serum and urine protein electrophoresis (sPEP/uPEP) are the standard methods for monitoring of multiple myeloma (MM). However, a method of detection with shorter half-life, such as serum-free light chain (FLC), could detect the response or progression earlier. In total, 450 MM patients were assessed in first, second, and third line. Response and progression were classified according to International myeloma working group guidelines. The overall median time to partial response or better was detectable significantly earlier with involved free light chain (iFLC) 1.94 months (IQR: 1.61-2.23) compared to sPEP 5.39 months (IQR: 3.88-7.00). In first line, iFLC detected progression earlier compared to sPEP, particularly in patients with progression more than 18 months after best response. In conclusion, a response observed by iFLC occurs at least a median of 3 months before response is detected by sPEP/uPEP.

Identifiants

pubmed: 33797301
doi: 10.1080/10428194.2021.1907370
doi:

Substances chimiques

Immunoglobulin Light Chains 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

2227-2234

Auteurs

Charlotte Gran (C)

Department of Medicine, Karolinska Institutet, Stockholm, Sweden.
Department of Clinical Chemistry, Karolinska University Laboratory, Stockholm, Sweden.

Gabriel Afram (G)

Department of Medicine, Karolinska Institutet, Stockholm, Sweden.
Haematology Center, Karolinska University Hospital, Stockholm, Sweden.

Johan Liwing (J)

Department of Medicine, Karolinska Institutet, Stockholm, Sweden.

Andre Verhoek (A)

Ingress-Health Nederland BV, Rotterdam, The Netherlands.

Hareth Nahi (H)

Department of Medicine, Karolinska Institutet, Stockholm, Sweden.
Haematology Center, Karolinska University Hospital, Stockholm, Sweden.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH